Education
About Us
Working with TipRanks
Follow Us
Haemonetics (HAE)
NYSE:HAE
HAE Stock Chart & Stats
$59.34
-$0.34(-0.44%)
At close: 4:00 PM EST
$59.34
-$0.34(-0.44%)
Day’s Range― - ―
52-Week Range$47.32 - $87.32
Previous CloseN/A
Volume53.78K
Average Volume (3M)809.92K
Market Cap
$2.76B
Enterprise Value$3.56B
Total Cash (Recent Filing)$363.37M
Total Debt (Recent Filing)$1.22B
Price to Earnings (P/E)15.9
Beta0.58
Next Earnings
May 07, 2026EPS Estimate
1.27Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)1.31
Shares Outstanding46,471,350
10 Day Avg. Volume1,059,765
30 Day Avg. Volume809,918
Financial Highlights & Ratios
PEG Ratio0.44
Price to Book (P/B)3.87
Price to Sales (P/S)2.34
P/FCF Ratio22.33
Enterprise Value/Market Cap1.29
Enterprise Value/Revenue2.70
Enterprise Value/Gross Profit4.62
Enterprise Value/Ebitda9.48
Forecast
1Y Price Target
$83.14Price Target Upside40.11% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering8
EPS Forecast (FY)4.91
Revenue Forecast (FY)$1.32B
Bulls Say, Bears Say
Bulls Say
Earnings Beat And Guidance UpgradeAnalyst notes revenue and earnings outperformance and an upward revision to guidance, which may boost investor confidence and reduce downside to near-term estimates.
Plasma Segment GrowthPlasma segment is delivering strong organic growth through market share gains and higher collection volumes, which can drive revenue upside and help improve company margins.
Profitability And Cash FlowAdjusted operating margins expanded across segments and the company generated solid operating and free cash flow, strengthening financial resilience and funding capacity for strategic initiatives.
Bears Say
Balance Sheet Leverage RiskCompany carries a substantial amount of debt on the balance sheet, introducing leverage risk that could limit flexibility if cash flow slows.
Hospital Segment WeaknessHospital segment underperformed due to softness in interventional technologies and related product headwinds, creating pressure on overall revenue trends.
Vascular Closure Commercialization RisksPerQseal lacks U.S. approval and faces intensified competition from newer closure devices, creating regulatory and commercial hurdles that could delay market penetration.
Haemonetics News
HAE FAQ
What was Haemonetics’s price range in the past 12 months?
Haemonetics lowest stock price was $47.31 and its highest was $87.32 in the past 12 months.
What is Haemonetics’s market cap?
Haemonetics’s market cap is $2.76B.
When is Haemonetics’s upcoming earnings report date?
Haemonetics’s upcoming earnings report date is May 07, 2026 which is in 86 days.
How were Haemonetics’s earnings last quarter?
Haemonetics released its earnings results on Feb 05, 2026. The company reported $1.31 earnings per share for the quarter, beating the consensus estimate of $1.25 by $0.06.
Is Haemonetics overvalued?
According to Wall Street analysts Haemonetics’s price is currently Undervalued.
Does Haemonetics pay dividends?
Haemonetics does not currently pay dividends.
What is Haemonetics’s EPS estimate?
Haemonetics’s EPS estimate is 1.27.
How many shares outstanding does Haemonetics have?
Haemonetics has 46,471,350 shares outstanding.
What happened to Haemonetics’s price movement after its last earnings report?
Haemonetics reported an EPS of $1.31 in its last earnings report, beating expectations of $1.25. Following the earnings report the stock price went down -1.41%.
Which hedge fund is a major shareholder of Haemonetics?
Currently, no hedge funds are holding shares in HAE
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Haemonetics Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$83.14 (40.11% Upside)
$83.14 (40.11% Upside)
Blogger Sentiment
Bullish
HAE Sentiment 70%
Sector Average 69%
Sector Average 69%
Hedge Fund Trend
Decreased
By 512.4K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Bought Shares
Worth $98.8K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Negative
Last 7 Days ▼ 0.9%
Last 30 Days ▼ 5.8%
Last 30 Days ▼ 5.8%
News Sentiment
Bullish
Bullish news 79%
Bearish news 20%
Bearish news 20%
Technicals
SMA
Positive
20 days / 200 days
Momentum
-5.79%
12-Months-Change
Fundamentals
Return on Equity
19.30%
Trailing 12-Months
Asset Growth
-1.60%
Trailing 12-Months
Company Description
Haemonetics
Haemonetics Corporation, a healthcare company, provides medical products and solutions. It operates through three segments: Plasma, Blood Center, and Hospital. The company offers automated plasma collection devices, related disposables, and software, including NexSys PCS and PCS2 plasmapheresis equipment and related disposables and intravenous solutions, as well as integrated information technology platforms for plasma customers to manage their donors, operations, and supply chain; and NexLynk DMS donor management system. It also provides automated blood component and manual whole blood collection systems, such as MCS brand apheresis equipment to collect specific blood components from the donor; disposable whole blood collection and component storage sets; SafeTrace Tx blood bank information system; and BloodTrack blood management software, a suite of blood management and bedside transfusion solutions that combines software with hardware components, as well as an extension of the hospital's blood bank information system. In addition, the company offers hospital products comprising TEG, ClotPro, and HAS hemostasis analyzer systems that provide a comprehensive assessment of a patient's overall hemostasis; TEG Manager software, which connects various TEG analyzers throughout the hospital, providing clinicians remote access to active and historical test results that inform treatment decisions; and Cell Saver Elite +, an autologous blood recovery system for cardiovascular, orthopedic, trauma, transplant, vascular, obstetrical, and gynecological surgeries. It markets and sells its products through direct sales force, independent distributors, and sales representatives. Haemonetics Corporation was founded in 1971 and is headquartered in Boston, Massachusetts.
HAE Company Deck
HAE Earnings Call
Q3 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
Overall the call was constructive: the company reported durable organic growth (notably in plasma and blood management technologies), margin expansion, accelerating cash generation, and raised guidance for revenue and free cash flow. These positives outweigh the clear near-term challenges in Interventional Technologies (driven by PFA adoption, OEM dynamics and order timing), vascular closure share loss in select accounts, and the lingering reported revenue impact from prior portfolio transitions. Management outlined funded remediation plans for IVT (MVP XL label expansion and PercuSeal Elite launch) and expects IVT to return to growth in FY2027, supporting a positive outlook.View all HAE earnings summariesHAE Stock 12 Month Forecast
Average Price Target
$83.14
▲(40.11% Upside)
Technical Analysis
Ownership Overview
1.38% Insiders
37.07% Mutual Funds
1.94% Other Institutional Investors
34.05% Public Companies and
Individual Investors